Cargando…

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor

Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Estella M, Knezevich, Jon T, Teply, Robyn M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640601/ https://www.ncbi.nlm.nih.gov/pubmed/23650452 http://dx.doi.org/10.2147/CPAA.S41859

Ejemplares similares

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Impact of Grapefruit Juice on the Antiplatelet Activity of Loading and Maintenance Doses of Clopidogrel in Healthy Volunteers
por: Campbell, Jennifer A., et al.
Publicado: (2014)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
por: Li, Pan, et al.
Publicado: (2016)

Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?
por: Suryanarayana Sharma, Pattanagere Manjunatha, et al.
Publicado: (2015)

Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity
por: Son, Gi-Ho, et al.
Publicado: (2019)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Ticagrelor Resistance in Cardiovascular Disease and Ischemic Stroke
por: He, Song, et al.
Publicado: (2023)

A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases
por: Tao, Luyuan, et al.
Publicado: (2022)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor
por: Na, Young-Guk, et al.
Publicado: (2019)

Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST‐segment elevation myocardial infarction
por: Welsh, Robert C., et al.
Publicado: (2021)

Influence of Antiplatelet Agents on the Lipid Composition of Platelet Plasma Membrane: A Lipidomics Approach with Ticagrelor and Its Active Metabolite
por: Lagoutte-Renosi, Jennifer, et al.
Publicado: (2021)

Massive Hyphaema Following Laser Iridotomy in a Patient on Dual Antiplatelet Therapy (Aspirin plus Ticagrelor): Case report and literature review
por: Galvis, Virgilio, et al.
Publicado: (2019)

Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
por: Gragnano, Felice, et al.
Publicado: (2022)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
por: Marcano, Ana Lucrecia, et al.
Publicado: (2022)

Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
por: Lombo, Bernardo, et al.
Publicado: (2011)

Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI
por: Bastiany, Alexandra, et al.
Publicado: (2018)

Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells
por: Elaskalani, Omar, et al.
Publicado: (2020)

Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling
por: Almquist, J, et al.
Publicado: (2016)

Risk of Cardiovascular Morbidity and Mortality in Relation to Temperature
por: Mathes, Robert, et al.
Publicado: (2013)

Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review
por: Edinoff, Amber N., et al.
Publicado: (2022)

Anger frequency and risk of cardiovascular morbidity and mortality
por: Titova, Olga E, et al.
Publicado: (2022)

Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi‐country observational study
por: Lesén, Eva, et al.
Publicado: (2021)

Ticagrelor Monotherapy After 3-Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial
por: Lee, Yong-Joon, et al.
Publicado: (2021)

Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial
por: Ono, Masafumi, et al.
Publicado: (2022)

Age‐Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
por: Kim, Byung Gyu, et al.
Publicado: (2021)

Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality
por: Clayton, Richard N.
Publicado: (2022)

Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
por: Liu, Lin, et al.
Publicado: (2018)

GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
por: Wallentin, Lars, et al.
Publicado: (2013)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
por: Wang, Zhe, et al.
Publicado: (2020)

Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
por: Niezgoda, Piotr, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_deec56vgkprbdt2bqucdnour5n